Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALZNNASDAQ:CDIONASDAQ:FNCHNASDAQ:PULM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$4.03-25.9%$6.09$3.06▼$135.54$4.36M-0.16412,723 shs2.01 million shsCDIOCardio Diagnostics$4.09-2.9%$9.30$3.40▼$53.10$7.11M3.791,530 shs28,875 shsFNCHFinch Therapeutics Group$13.50-0.9%$13.21$0.82▼$15.85$21.88M1.272,277 shs1,110 shsPULMPulmatrix$8.56+4.4%$6.39$1.78▼$10.40$31.24M1.38133,123 shs33,150 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro-25.92%+10.41%-32.15%-45.39%-92.25%CDIOCardio Diagnostics-2.85%+3.54%-67.91%-69.66%-80.28%FNCHFinch Therapeutics Group-0.94%+3.85%+8.00%-14.50%+1,433.92%PULMPulmatrix+4.39%+25.70%+29.50%+5.94%+356.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALZNAlzamend Neuro3.3128 of 5 stars3.54.00.00.03.04.20.0CDIOCardio Diagnostics2.9162 of 5 stars3.55.00.00.03.01.70.0FNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AN/AN/AN/APULMPulmatrix0.7976 of 5 stars0.05.00.00.03.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALZNAlzamend Neuro 3.00Buy$180.004,366.50% UpsideCDIOCardio Diagnostics 3.00Buy$60.001,366.99% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/APULMPulmatrix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALZN, CDIO, FNCH, and PULM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/17/2025ALZNAlzamend NeuroAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$288.00 ➝ $180.00(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALZNAlzamend NeuroN/AN/AN/AN/A($3.52) per shareN/ACDIOCardio Diagnostics$19.90K357.38N/AN/A$0.14 per share29.21FNCHFinch Therapeutics Group$110K197.10N/AN/A$14.25 per share0.95PULMPulmatrix$1.92M16.26N/AN/A$4.93 per share1.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALZNAlzamend Neuro-$9.95MN/A0.00N/AN/AN/AN/A-289.14%7/29/2025 (Estimated)CDIOCardio Diagnostics-$8.38MN/A0.00∞N/A-22,732.03%-258.85%-191.20%8/12/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/APULMPulmatrix-$14.12M-$3.34N/A∞N/A-96.51%-45.97%-30.72%8/11/2025 (Estimated)Latest ALZN, CDIO, FNCH, and PULM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CDIOCardio Diagnostics-$0.06-$0.97-$0.91-$0.97$0.05 million$0.00 million5/15/2025Q1 2025PULMPulmatrixN/A-$0.50N/A-$0.50N/AN/A3/21/2025Q4 2024PULMPulmatrixN/A-$0.54N/A-$0.54N/AN/A3/10/2025Q3 2025ALZNAlzamend Neuro-$2.61-$1.71+$0.90-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALZNAlzamend NeuroN/AN/AN/AN/AN/ACDIOCardio DiagnosticsN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALZNAlzamend NeuroN/A3.803.80CDIOCardio DiagnosticsN/A8.508.50FNCHFinch Therapeutics GroupN/A3.873.87PULMPulmatrixN/A19.4019.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALZNAlzamend Neuro49.61%CDIOCardio Diagnostics8.06%FNCHFinch Therapeutics Group21.77%PULMPulmatrix11.84%Insider OwnershipCompanyInsider OwnershipALZNAlzamend Neuro30.21%CDIOCardio Diagnostics22.30%FNCHFinch Therapeutics Group44.90%PULMPulmatrix0.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALZNAlzamend Neuro4801,0004.86 millionNo DataCDIOCardio Diagnostics11.74 million40.52 millionNot OptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataPULMPulmatrix203.65 million3.63 millionNot OptionableALZN, CDIO, FNCH, and PULM HeadlinesRecent News About These CompaniesPulmatrix set for merger with Cullgen, seeks asset divestmentMay 17, 2025 | uk.investing.comPulmatrix Inc.: Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for AssetsMay 15, 2025 | finanznachrichten.dePulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for AssetsMay 15, 2025 | prnewswire.comAspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, PulmocideApril 3, 2025 | theglobeandmail.comPulmatrix Reports 2024 Financials and Merger PlansMarch 25, 2025 | tipranks.comPulmatrix Inc.: Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for AssetsMarch 21, 2025 | finanznachrichten.dePulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for AssetsMarch 21, 2025 | prnewswire.comPulmatrix revises bylaws, changes voting standardsFebruary 14, 2025 | msn.comCullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic PainJanuary 23, 2025 | finance.yahoo.comHow to Take Advantage of moves in (PULM)January 11, 2025 | news.stocktradersdaily.comWhen the Price of (PULM) Talks, People ListenDecember 11, 2024 | news.stocktradersdaily.comPulmatrix Inc (PULM) Stock: Surpassing Expectations in the MarketNovember 19, 2024 | bovnews.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of ShareholdersNovember 15, 2024 | accesswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULMNovember 15, 2024 | bakersfield.comPULM INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Pulmatrix, Inc. MergerNovember 14, 2024 | accesswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULMNovember 14, 2024 | globenewswire.comPulmatrix Inc.: Pulmatrix and Cullgen Announce Proposed MergerNovember 14, 2024 | finanznachrichten.dePULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to ShareholdersNovember 14, 2024 | joplinglobe.comFramingham-based biopharma company announces merger agreement with San Diego firmNovember 14, 2024 | wbjournal.comPulmatrix Shares Surge on Merger with CullgenNovember 14, 2024 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALZN, CDIO, FNCH, and PULM Company DescriptionsAlzamend Neuro NASDAQ:ALZN$4.03 -1.41 (-25.92%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$3.88 -0.15 (-3.62%) As of 05/30/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Cardio Diagnostics NASDAQ:CDIO$4.09 -0.12 (-2.85%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$4.09 +0.00 (+0.10%) As of 05/30/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.Finch Therapeutics Group NASDAQ:FNCH$13.50 -0.13 (-0.94%) As of 05/30/2025 02:36 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Pulmatrix NASDAQ:PULM$8.56 +0.36 (+4.39%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$9.00 +0.44 (+5.13%) As of 05/30/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
